Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by NABIL AHMED and MEENAKSHI HEGDE.
NABIL AHMED
Connection Strength
6.126
MEENAKSHI HEGDE
  1. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 Jun; 5(6):880-894.
    View in: PubMed
    Score: 0.970
  2. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2021 07 01; 131(13).
    View in: PubMed
    Score: 0.798
  3. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549.
    View in: PubMed
    Score: 0.747
  4. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
    View in: PubMed
    Score: 0.566
  5. Cellular immunotherapy for pediatric solid tumors. Cytotherapy. 2015 Jan; 17(1):3-17.
    View in: PubMed
    Score: 0.494
  6. Novel approaches and mechanisms of immunotherapy for glioblastoma. Discov Med. 2014 Mar; 17(93):145-54.
    View in: PubMed
    Score: 0.480
  7. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov; 21(11):2087-101.
    View in: PubMed
    Score: 0.462
  8. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018 03 27; 20(4):506-518.
    View in: PubMed
    Score: 0.159
  9. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
    View in: PubMed
    Score: 0.152
  10. Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. J Neurooncol. 2015 Nov; 125(2):307-15.
    View in: PubMed
    Score: 0.133
  11. Polystyrene microspheres enable 10-color compensation for immunophenotyping of primary human leukocytes. Cytometry A. 2015 Nov; 87(11):1038-46.
    View in: PubMed
    Score: 0.132
  12. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
    View in: PubMed
    Score: 0.129
  13. Human cytomegalovirus antigens in malignant gliomas as targets for adoptive cellular therapy. Front Oncol. 2014; 4:338.
    View in: PubMed
    Score: 0.126
  14. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68.
    View in: PubMed
    Score: 0.104
  15. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
    View in: PubMed
    Score: 0.061
  16. Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
    View in: PubMed
    Score: 0.057
  17. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
    View in: PubMed
    Score: 0.054
  18. Author Correction: Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2021 Jun; 27(6):1117-1120.
    View in: PubMed
    Score: 0.050
  19. A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma. Sci Transl Med. 2021 05 05; 13(592).
    View in: PubMed
    Score: 0.049
  20. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021 06; 18(6):379-393.
    View in: PubMed
    Score: 0.049
  21. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020 05; 26(5):720-731.
    View in: PubMed
    Score: 0.046
  22. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2021 01; 35(1):75-89.
    View in: PubMed
    Score: 0.046
  23. Immunotherapy for pediatric brain tumors: past and present. Neuro Oncol. 2019 10 09; 21(10):1226-1238.
    View in: PubMed
    Score: 0.044
  24. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650.
    View in: PubMed
    Score: 0.040
  25. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431.
    View in: PubMed
    Score: 0.040
  26. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018 01 15; 78(2):489-500.
    View in: PubMed
    Score: 0.039
  27. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541.
    View in: PubMed
    Score: 0.039
  28. T cells redirected to interleukin-13Ra2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ra1. Cytotherapy. 2014 Aug; 16(8):1121-31.
    View in: PubMed
    Score: 0.030
  29. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids. 2013 Jul 09; 2:e105.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.